IN VIVO THERAPEUTIC SUCCESS OF MICRORNA-155 (MIR-155) ANTAGOMIR IN A MOUSE MODEL OF LUPUS ALVEOLAR HAEMORRHAGE

Y Wang*, S Zhou, N Shen. Renli Hospital- School of Medicine- Shanghai JiaoTong University, Department of Rheumatology, Shanghai, China

10.1136/lupus-2017-000215.333

Background and aims Diffuse alveolar haemorrhage (DAH) is a rare but life-threatening complication of systemic lupus erythematosus (SLE). Pristane-treated B6 mice develop severe DAH within 2 weeks of treatment. Microrna-155 (mir-155) is a pleiotropic microRNA that plays a crucial role in the regulation of immune responses. The purpose of this study was to examine the role of mir-155 in the development of DAH in pristane-induced lupus using mir-155-knockout (mir-155/-) mice and mir-155 antagonir to silence mir-155.

Methods DAH was induced by an intraperitoneal injection of 0.5 mL of pristane. Mir-155 antagonir was intravenously administrated to silence mir-155 expression. Lung tissues were collected for RNA extraction and were embedded in paraffin for sectioning. Gene expression profiling data were analysed using Ingenuity Pathway Analysis. Real time q-PCR was used for single validation. Luciferase reporter assay and RNA-Ago2 immunoprecipitation were performed for target validation.

Results Mir-155 expression was significantly increased in the development of DAH. Disease progression was reduced in mir-155/- mice and by in vitro silencing of mir-155 using mir-155 antagonir. Mir-155 silencing dampened pristane-induced ectopic activation of multiple inflammatory pathways, and reduced the expression of pro-inflammatory cytokines. Several negative regulators of nuclear factor (NF)-κB signalling were inhibited by pristane, and were re-activated in mir-155-/-. In particular, the anti-inflammatory factor peroxisome proliferator-activated receptor-α was identified as a direct target of mir-155.

Conclusions Mir-155 promotes pristane-induced lung inflammation. Mir-155 contributes to ectopic activation of NF-κB signalling pathways by targeting multiple negative regulators. Mir-155 antagonir may be a promising therapeutic strategy for treating acute lung inflammation in lupus.

SEVERAL IL-18 AS BIOMARKER IN PREDICTING LONG-TERM RENAL OUTCOME AMONG PEDIATRIC-ONSET SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS

JL 1KW Yeh*, CY Wu, HY Yang, JL 1Chang Gung Memorial Hospital, Paediatrics, Taoyuan, Taiwan R.O.C, 1Chang Gung Memorial Hospital, Nephrology, Taoyuan, Taiwan R.O.C

10.1136/lupus-2017-000215.334

Background and Aims An urge of biomarker identification is needed to better monitor lupus nephritis (LN) disease activity, guide clinical treatment, and predict patient’s long-term outcome. With the proinflammatory effect and its association with inflamasomes, the significance of interleukin-18 (IL-18) among pediatric-onset systemic lupus erythematosus (pSLE) patient.

Methods In a pSLE cohort of 96 patients with an average follow-up period of 10.39±3.31 years, clinical data and laboratory workups including serum IL-18 were collected at time of disease onset and 6 months after treatment despite their initial renal status. Through Cox regression analysis, the parameters at baseline and at 6 months posttreatment were carefully analysed.

Results Average age of all cases was 12.74±3.01 years old and 65 of them underwent renal biopsy at the time of diagnosis. Nine(9.38%) progressed to end-stage renal disease (ESRD) and 2 (0.8%) died during follow-up. Through multivariate analysis, serum IL-18 level 6 months posttreatment was found to be the most unfavourable factor associating poor clinical outcome despite patient’s initial renal status. The presentation of serum IL-18 in its correlation with SLE global disease activity as well as the presence and severity of LN were all significant (p<0.001, p=0.03, and p=0.02, respectively). The histological classification of LN was not associated with the level of IL-18 among the pSLE patients (p=0.64).

Conclusions The role of serum IL-18 as biomarker representing global disease activity and status of renal flares among pSLE population was shown for the first time. Additionally, we have identified IL-18 at 6 months posttreatment a novel marker for long-term renal outcome prediction.

MICRONRNA-21 IS A CRITICAL REGULATOR OF AUTOIMMUNITY THROUGH PROMOTING EFFECCTOR AND METABOLIC FUNCTION OF PATHOGENIC TH17 CELLS

X Yu*, D Dai, N Shen. Renli Hospital- School of Medicine- Shanghai JiaoTong University, Department of Rheumatology, Shanghai, China

10.1136/lupus-2017-000215.335

Background and aims Systemic lupus erythematosus is a prototypical autoimmune disease that causes mortality and morbidity worldwide. Recent studies suggest proinflammatory TH17 cells are key pathogenic factors that contribute to lupus nephritis. Our group previously demonstrated that microRNA-21 was highly upregulated in CD4+ T cells from both lupus patients and lupus-prone mice. However, the role of microRNA-21 in pathogenic TH17 cells and they-mediated autoimmune diseases is still unclear. In this study, we systemically dissect the role of microRNA-21 in the differentiation and effector function of pathogenic TH17 cells.

Methods MicroRNA-21 knockout and conditional knockout mice were generated. EAE was induced to study the role of microRNA-21 in pathogenic TH17 cell-mediated autoimmune diseases. RNA-seq, RIP-seq and DAVID bioinformatic analysis were conducted to find key microRNA-21 regulated pathway and molecular targets in pathogenic TH17 cells. Metabolic assays were done to study the glycolytic activity of microRNA-21-deficient pathogenic TH17 cells.

Results In this study, we demonstrate that IL-6-STAT3 signalling induced microRNA-21 is essential for the late stage commitment and maintenance of pathogenic TH17 cells by targeting key regulators. MicroRNA-21-deficient TH17 cells express less pathogenic TH17 signature genes and show less glycolytic activity. Conditional deletion of microRNA-21 in CD4+ T cells protects mice from EAE while loss of microRNA-21 expression by dendritic cells and myeloid cells do not.

Conclusions These findings suggest that microRNA-21 is a novel cell-intrinsic regulator of the commitment and metabolic function of pathogenic TH17 cells. It may be a potential therapeutic candidate with which to reprogram the immune system and help prevent and treat autoimmune diseases.